Induction of NQO1 and Neuroprotection by a Novel Compound KMS04014 in Parkinson’s Disease Models

Journal of Molecular Neuroscience

Volumn 56, Issue 2, 2015, Pages 263-272

  Son, Hyo Jin ^a   Choi, Ji Hyun ^a   Lee, Ji Ae ^a   Kim, Dong Jin ^b   Shin, Kye Jung ^c   Hwang, Onyou ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Korea Institute of Science and Technology   (South Korea)

^c The Catholic University of Korea   (South Korea)

Author keywords

KMS04014; Neuroprotection; NQO1; Parkinson s disease; Substantia nigra

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; ADENOSINE TRIPHOSPHATE; ANTIPARKINSON AGENT; BETA ACTIN; HYDROGEN PEROXIDE; KMS 04014; MESSENGER RNA; NEUROPROTECTIVE AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TETRAHYDROBIOPTERIN; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; 1,2-DI(2-METHOXY-4-(2-CARBOXYVINYL))PHENOXYETHANE; ANTIOXIDANT; COUMARIC ACID; NFE2L2 PROTEIN, MOUSE; NQO1 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; GENE EXPRESSION; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN EXPRESSION; PROTON NUCLEAR MAGNETIC RESONANCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBSTANTIA NIGRA; THIN LAYER CHROMATOGRAPHY; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CYTOLOGY; DRUG EFFECTS; GENETICS; METABOLISM; MPTP POISONING; PROTEIN TRANSPORT; SYNTHESIS; TUMOR CELL LINE;

ANIMALIA; MUS;

ANIMALS; ANTIOXIDANTS; CELL LINE, TUMOR; COUMARIC ACIDS; DOPAMINERGIC NEURONS; MALE; MICE; MICE, INBRED C57BL; MPTP POISONING; NAD(P)H DEHYDROGENASE (QUINONE); NEUROPROTECTIVE AGENTS; NF-E2-RELATED FACTOR 2; PROTEIN TRANSPORT; RNA, MESSENGER; SUBSTANTIA NIGRA;

EID: 84930480947     PISSN: 08958696     EISSN: 15591166     Source Type: Journal    
DOI: 10.1007/s12031-015-0516-7     Document Type: Article

References (61)

1. Asanuma M, Miyazaki I, Ogawa N (2003) Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease. Neurotox Res 5:165–176
2. Belluzzi E, Bisaglia M, Lazzarini E, Tabares LC, Beltramini M, Bubacco L (2012) Human SOD2 modification by dopamine quinones affects enzymatic activity by promoting its aggregation: possible implications for Parkinson's disease. PLoS One 7:e38026
3. Beyer RE, Segura-Aguilar J, di Bernardo S et al (1997) The two-electron quinone reductase DT-diaphorase generates and maintains the antioxidant (reduced) form of coenzyme Q in membranes. Mol Asp Med 18(Suppl):S15–S23
4. Bisaglia M, Soriano ME, Arduini I, Mammi S, Bubacco L (2010) Molecular characterization of dopamine-derived quinones reactivity toward NADH and glutathione: implications for mitochondrial dysfunction in Parkinson disease. Biochim Biophys Acta 1802:699–706
5. Cavelier G, Amzel LM (2001) Mechanism of NAD(P)H:quinone reductase: Ab initio studies of reduced flavin. Proteins 43:420–432
6. Cho Y, Son HJ, Kim EM et al (2009) Doxycycline is neuroprotective against nigral dopaminergic degeneration by a dual mechanism involving MMP-3. Neurotox Res 16:361–371
7. Choi HJ, Jang YJ, Kim HJ, Hwang O (2000) Tetrahydrobiopterin is released from and causes preferential death of catecholaminergic cells by oxidative stress. Mol Pharmacol 58:633–640
8. Choi HJ, Kim SW, Lee SY, Hwang O (2003) Dopamine-dependent cytotoxicity of tetrahydrobiopterin: a possible mechanism for selective neurodegeneration in Parkinson's disease. J Neurochem 86:143–152
9. Choi HJ, Lee SY, Cho Y, Hwang O (2005) Inhibition of vesicular monoamine transporter enhances vulnerability of dopaminergic cells: relevance to Parkinson's disease. Neurochem Int 46:329–335
10. Choi DH, Kim EM, Son HJ et al (2008) A novel intracellular role of matrix metalloproteinase-3 during apoptosis of dopaminergic cells. J Neurochem 106:405–415
11. Conway KA, Rochet JC, Bieganski RM, Lansbury PT Jr (2001) Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294:1346–1349
12. Duffy S, So A, Murphy TH (1998) Activation of endogenous antioxidant defenses in neuronal cells prevents free radical-mediated damage. J Neurochem 71:69–77
13. Franklin KBJ, Paxinos G (1997) The mouse brain in stereotaxic coordinates. Academic Press, San Diego, pp 59–67
14. Fujisawa S, Atsumi T, Kadoma Y, Sakagami H (2002) Antioxidant and prooxidant action of eugenol-related compounds and their cytotoxicity. Toxicology 177:39–54
15. Fujisawa S, Atsumi T, Kadoma Y, Ishihara M, Ito S, Yokoe I (2004) Kinetic radical scavenging activity and cytotoxicity of 2-methoxy- and 2-t-butyl-substituted phenols and their dimers. Anticancer Res 24:3019–3026
16. Fujisawa S, Atsumi T, Murakami Y, Kadoma Y (2005) Dimerization, ROS formation, and biological activity of o-methoxyphenols. Arch Immunol Ther Exp (Warsz) 53:28–38
17. Graham DG, Tiffany SM, Bell WR Jr, Gutknecht WF (1978) Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol 14:644–653
18. Han JM, Lee YJ, Lee SY et al (2007) Protective effect of sulforaphane against dopaminergic cell death. J Pharmacol Exp Ther 321:249–256
19. Hara H, Ohta M, Ohta K, Kuno S, Adachi T (2003) Increase of antioxidative potential by tert-butylhydroquinone protects against cell death associated with 6-hydroxydopamine-induced oxidative stress in neuroblastoma SH-SY5Y cells. Brain Res Mol Brain Res 119:125–131
20. Harada S, Fujii C, Hayashi A, Ohkoshi N (2001) An association between idiopathic Parkinson's disease and polymorphisms of phase II detoxification enzymes: glutathione S-transferase M1 and quinone oxidoreductase 1 and 2. Biochem Biophys Res Commun 288:887–892
21. Hastings TG, Zigmond MJ (1997) Loss of dopaminergic neurons in parkinsonism: possible role of reactive dopamine metabolites. J Neural Transm Suppl 49:103–110
22. Hirata A, Murakami Y, Atsumi T et al (2005) Ferulic acid dimer inhibits lipopolysaccharide-stimulated cyclooxygenase-2 expression in macrophages. In Vivo 19:849–853
23. Hwang O, Baker H, Gross S, Joh TH (1998) Localization of GTP cyclohydrolase in monoaminergic but not nitric oxide-producing cells. Synapse 28:140–153
24. Hwang O, Kim G, Jang YJ et al (2001) Synthetic phytoceramides induce apoptosis with higher potency than ceramides. Mol Pharmacol 59:1249–1255
25. Inoue M, Suzuki R, Koide T, Sakaguchi N, Ogihara Y, Yabu Y (1994) Antioxidant, gallic acid, induces apoptosis in HL-60RG cells. Biochem Biophys Res Commun 204:898–904
26. Itoh K, Wakabayashi N, Katoh Y et al (1999) Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 13:76–86
27. Jazwa A, Rojo AI, Innamorato NG, Hesse M, Fernandez-Ruiz J, Cuadrado A (2011) Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism. Antioxid Redox Signal 14:2347–2360
28. Jia Z, Zhu H, Misra HP, Li Y (2008) Potent induction of total cellular GSH and NQO1 as well as mitochondrial GSH by 3H-1,2-dithiole-3-thione in SH-SY5Y neuroblastoma cells and primary human neurons: protection against neurocytotoxicity elicited by dopamine, 6-hydroxydopamine, 4-hydroxy-2-nonenal, or hydrogen peroxide. Brain Res 1197:159–169
29. Jia Z, Zhu H, Li Y, Misra HP (2009) Cruciferous nutraceutical 3H-1,2-dithiole-3-thione protects human primary astrocytes against neurocytotoxicity elicited by MPTP, MPP(+), 6-OHDA, HNE and acrolein. Neurochem Res 34:1924–1934
30. Joseph P, Long DJ 2nd, Klein-Szanto AJ, Jaiswal AK (2000) Role of NAD(P)H:quinone oxidoreductase 1 (DT diaphorase) in protection against quinone toxicity. Biochem Pharmacol 60:207–214
31. Kim ST, Choi JH, Chang JW, Kim SW, Hwang O (2005) Immobilization stress causes increases in tetrahydrobiopterin, dopamine, and neuromelanin and oxidative damage in the nigrostriatal system. J Neurochem 95:89–98
32. Kim EM, Shin EJ, Choi JH et al (2010) Matrix metalloproteinase-3 is increased and participates in neuronal apoptotic signaling downstream of caspase-12 during endoplasmic reticulum stress. J Biol Chem 285:16444–16452
33. Kobayashi A, Kang MI, Okawa H et al (2004) Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 24:7130–7139
34. LaVoie MJ, Ostaszewski BL, Weihofen A, Schlossmacher MG, Selkoe DJ (2005) Dopamine covalently modifies and functionally inactivates parkin. Nat Med 11:1214–1221
35. Lee SY, Moon Y, Choi DH, Choi HJ, Hwang O (2007) Particular vulnerability of rat mesencephalic dopaminergic neurons to tetrahydrobiopterin: relevance to Parkinson's disease. Neurobiol Dis 25:112–120
36. Lee JA, Kim JH, Woo SY et al (2014) A novel compound VSC2 has anti-inflammatory and antioxidant properties in microglia and in Parkinson's disease animal model. Br J Pharmacol. doi:10.1111/bph.12973
37. Lim JH, Kim KM, Kim SW, Hwang O, Choi HJ (2008) Bromocriptine activates NQO1 via Nrf2-PI3K/Akt signaling: novel cytoprotective mechanism against oxidative damage. Pharmacol Res 57:325–331
38. Ma ZC, Hong Q, Wang YG et al (2010) Ferulic acid protects human umbilical vein endothelial cells from radiation induced oxidative stress by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase pathways. Biol Pharm Bull 33:29–34
39. Martinez-Vicente M, Talloczy Z, Kaushik S et al (2008) Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J Clin Invest 118:777–788
40. Maurya DK, Devasagayam TP (2010) Antioxidant and prooxidant nature of hydroxycinnamic acid derivatives ferulic and caffeic acids. Food Chem Toxicol 48:3369–3373
41. Miyazaki I, Asanuma M, Diaz-Corrales FJ et al (2006) Methamphetamine-induced dopaminergic neurotoxicity is regulated by quinone-formation-related molecules. FASEB J 20:571–573
42. Murakami Y, Shoji M, Ogiwara T, Tanaka S, Yokoe I, Fujisawa S (2006) Preventive effect of ortho dimer of butylated hydroxyanisole on activator protein-1 activation and cyclooxygenase-2 expression in macrophages stimulated by fimbriae of Porphyromonas gingivalis, an oral anaerobe. Anticancer Res 26:2915–2920
43. Schmued LC, Stowers CC, Scallet AC, Xu L (2005) Fluoro-Jade C results in ultra high resolution and contrast labeling of degenerating neurons. Brain Res 1035:24–31
44. Sergediene E, Jonsson K, Szymusiak H, Tyrakowska B, Rietjens IM, Cenas N (1999) Prooxidant toxicity of polyphenolic antioxidants to HL-60 cells: description of quantitative structure-activity relationships. FEBS Lett 462:392–396
45. Siebert A, Desai V, Chandrasekaran K, Fiskum G, Jafri MS (2009) Nrf2 activators provide neuroprotection against 6-hydroxydopamine toxicity in rat organotypic nigrostriatal cocultures. J Neurosci Res 87:1659–1669
46. Siegel D, Bolton EM, Burr JA, Liebler DC, Ross D (1997) The reduction of alpha-tocopherolquinone by human NAD(P)H: quinone oxidoreductase: the role of alpha-tocopherolhydroquinone as a cellular antioxidant. Mol Pharmacol 52:300–305
47. Siegel D, Anwar A, Winski SL, Kepa JK, Zolman KL, Ross D (2001) Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1. Mol Pharmacol 59:263–268
48. Siegel D, Gustafson DL, Dehn DL et al (2004) NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger. Mol Pharmacol 65:1238–1247
49. Son HJ, Lee JA, Shin N et al (2012) A novel compound PTIQ protects the nigral dopaminergic neurones in an animal model of Parkinson's disease induced by MPTP. Br J Pharmacol 165:2213–2227
50. Thyagaraju BM, Muralidhara (2008) Ferulic acid supplements abrogate oxidative impairments in liver and testis in the streptozotocin-diabetic rat. Zool Sci 25:854–860
51. Van Laar VS, Mishizen AJ, Cascio M, Hastings TG (2009) Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cells. Neurobiol Dis 34:487–500
52. van Muiswinkel FL, de Vos RA, Bol JG et al (2004) Expression of NAD(P)H:quinone oxidoreductase in the normal and Parkinsonian substantia nigra. Neurobiol Aging 25:1253–1262
53. Venugopal R, Jaiswal AK (1996) Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene. Proc Natl Acad Sci U S A 93:14960–14965
54. Wang N, Wang Y, Yu G, Yuan C, Ma J (2011) Quinoprotein adducts accumulate in the substantia nigra of aged rats and correlate with dopamine-induced toxicity in SH-SY5Y cells. Neurochem Res 36:2169–2175
55. Woo SY, Kim JH, Moon MK et al (2014) Discovery of vinyl sulfones as a novel class of neuroprotective agents toward Parkinson's disease therapy. J Med Chem 57:1473–1487
56. Yeh CT, Ching LC, Yen GC (2009) Inducing gene expression of cardiac antioxidant enzymes by dietary phenolic acids in rats. J Nutr Biochem 20:163–171
57. Zafar KS, Inayat-Hussain SH, Siegel D, Bao A, Shieh B, Ross D (2006a) Overexpression of NQO1 protects human SK-N-MC neuroblastoma cells against dopamine-induced cell death. Toxicol Lett 166:261–267
58. Zafar KS, Siegel D, Ross D (2006b) A potential role for cyclized quinones derived from dopamine, DOPA, and 3,4-dihydroxyphenylacetic acid in proteasomal inhibition. Mol Pharmacol 70:1079–1086
59. Zahid M, Saeed M, Yang L, Beseler C, Rogan E, Cavalieri EL (2011) Formation of dopamine quinone-DNA adducts and their potential role in the etiology of Parkinson's disease. IUBMB Life 63:1087–1093
60. Zhou ZD, Lim TM (2009) Dopamine (DA) induced irreversible proteasome inhibition via DA derived quinones. Free Radic Res 43:417–430
61. Zhou ZD, Lim TM (2010) Glutathione conjugates with dopamine-derived quinones to form reactive or non-reactive glutathione-conjugates. Neurochem Res 35:1805–1818